We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+56.1%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$214M
AUM Growth
+$68.2M
Cap. Flow
+$10.8M
Cap. Flow %
5.05%
Top 10 Hldgs %
96.36%
Holding
21
New
3
Increased
4
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
AIMT
Aimmune Therapeutics
AIMT
+$9.45M
2
AERI
Aerie Pharmaceuticals
AERI
+$7.78M
3
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$7M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$6.58M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$4.73M

Top Sells

Rank Stock Value
1
WVE icon
Wave Life Sciences
WVE
+$5.73M
2
ARDX icon
Ardelyx
ARDX
+$5.25M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$4.47M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$3.62M
5
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$3.27M

Sector Composition

Rank Sector Weight
1 Healthcare 63.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
$64.1M 29.95%
1,697,884
+352,571
+26% +$7.78M
ALDR
2
DELISTED
Alder Biopharmaceuticals
ALDR
$52M 24.29%
1,585,683
-14,500
-0.9% -$442K
WVE icon
3
Wave Life Sciences
WVE
$1.13B
$23.6M 11.04%
727,496
-242,608
-25% -$5.73M
AIMT
4
DELISTED
Aimmune Therapeutics
AIMT
$14M 6.56%
935,020
+700,000
+298% +$9.45M
NTLA icon
5
Intellia Therapeutics
NTLA
$1.49B
$13M 6.08%
763,688
– –
GBT
6
DELISTED
Global Blood Therapeutics, Inc.
GBT
$10.5M 4.91%
455,590
-234,679
-34% -$4.47M
NSTG
7
DELISTED
NanoString Technologies, Inc.
NSTG
$9.7M 4.53%
485,600
+414,600
+584% +$6.58M
MNTA
8
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$6.96M 3.25%
+595,513
New +$7M
PTGX icon
9
Protagonist Therapeutics
PTGX
$8.72B
$6.29M 2.94%
+346,281
New +$4.73M
EPZM
10
DELISTED
Epizyme, Inc
EPZM
$6.02M 2.81%
611,777
+100,000
+20% +$913K
LRMR icon
11
Larimar Therapeutics
LRMR
$392M
$1.78M 0.83%
44,791
– –
AKTX
12
Akari Therapeutics
AKTX
$14.4M
$1.68M 0.78%
246
– –
LPCN icon
13
Lipocine
LPCN
$17.6M
$1.35M 0.63%
17,802
– –
BOLD
14
DELISTED
Audentes Therapeutics, Inc
BOLD
$1.19M 0.55%
+66,553
New +$1.01M
OREX
15
DELISTED
Orexigen Therapeutics, Inc.
OREX
$844K 0.39%
254,257
-1
-0% -$4
SYRS
16
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$832K 0.39%
6,000
-9,000
-60% -$1.14M
BDSI
17
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$127K 0.06%
47,158
-23,019
-33% -$58.5K
ARDX icon
18
Ardelyx
ARDX
$1.25B
– –
-601,485
Closed -$5.25M
BLCM
19
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-20,599
Closed -$2.67M
AVXS
20
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-95,173
Closed -$3.62M
NDRM
21
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-201,469
Closed -$3.27M

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q3 2016 Portfolio in Review

As of Q3 2016, Foresite Capital Management III held 21 positions worth $214M, up 47% from $146M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Foresite Capital Management III deployed $10.8M of net new capital in Q3 2016, opening 3 new positions and adding to 4 existing holdings. Its largest new stake was Momenta Pharmaceuticals, Inc.: 595,513 shares worth $6.96M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 82% a quarter earlier.

On the sell side, the largest reduction was Wave Life Sciences, an estimated $5.73M trimmed.

  • Foresite Capital Management III's largest Q3 2016 buy was Momenta Pharmaceuticals, Inc.: 595,513 shares worth $6.96M.
  • Foresite Capital Management III added most to Aimmune Therapeutics in Q3 2016, an estimated $9.45M increase.
  • Foresite Capital Management III's biggest Q3 2016 reduction was Wave Life Sciences, cutting an estimated $5.73M.
  • Foresite Capital Management III fully exited Ardelyx in Q3 2016, selling an estimated $5.25M.
  • Foresite Capital Management III's ten largest holdings make up 96% of its $214M portfolio in Q3 2016.
  • Foresite Capital Management III opened 3 new positions and closed 4 in Q3 2016.
  • Foresite Capital Management III's portfolio value rose 47% quarter-over-quarter to $214M.

Based on Foresite Capital Management III's 13F filing for Q3 2016, filed 14 Nov 2016.